Latest from Kromek

Globally, the probability of a radiological or nuclear (R&N) event occurring is increasing. Past nuclear disasters such as Fukushima and Chernobyl demonstrate the cascade of short and long-term consequences that occur when decision-makers act reactively without up-to-date data. These incidents quickly spiral out of control without the necessary strategies or technology to manage them. This is especially significant with lots of international borders in proximity.

On 26th January 2023, Kromek hosted the annual Emerging Technology and Future Concept Showcase at the Royal Academy of Engineering in Central London. This year’s event was designed to demonstrate the breadth of Kromek’s Radiological and Biological Threat Detection capabilities to invited industry guests and to provide a forum for constructive debate with a range of stakeholders.

Innovate UK provides funds for two projects to advance low-dose molecular breast imaging solution.

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces its interim results for the six months ended 31 October 2022.

Kromek Group is pleased to announce that it has entered into a distribution agreement with Smiths Detection, a global leader in threat detection and security screening technologies. A significant expansion of agreement to include distribution of Kromek’s radiation detection solutions in the Middle East and certain markets in Asia and Australasia

Kromek wins two contracts totalling £1.5m for the supply of our D3M and D3S-based products for European government end-user.